Results
|
1.
|
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. MedStar authors:
Year: 2014
Citation: - Journal of Clinical Oncology. 32(33):3744-52, 2014 Nov 20.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Colon-Otero G, Davidson NE, Geyer CE Jr, Gralow J, Jeong JH, Mamounas E, Martino S, Perez EA, Rastogi P, Romond EH, Sledge G, Suman VJ, Swain SM, Winer EP, Wolmark N, Zujewski JA
|
|
2.
|
Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). MedStar authors:
Citation: - Cancer. 119(8):1555-61, 2013 Apr 15.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase II
- Journal Article
- Multicenter Study
- Research Support, Non-U.S. Gov't
All authors: - Araujo DM, Baker LH, George S, Hensley ML, Maki RG, Priebat DA, Soslow RA, Sutton G, Wathen JK
|
|
3.
|
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. [Review] MedStar authors:
Year: 2014
Citation: - Lancet. 384(9938):164-72, 2014 Jul 12.
Medline publication type:
- Journal Article
- Meta-Analysis
- Research Support, U.S. Gov't, P.H.S.
- Review
All authors: - Baselga J, Bergh J, Blohmer J, Blumenthal G, Bogaerts J, Bonnefoi H, Cameron D, Cortazar P, Costantino JP, Ditsch N, Eidtmann H, Eiermann W, Fasching PA, Gerber B, Geyer CE Jr, Gianni L, Justice R, Loibl S, Mamounas EP, Mehta K, Paik S, Pazdur R, Perou C, Piccart M, Prowell T, Rastogi P, Semiglazov V, Slaets L, Sridhara R, Swain SM, Tang S, Untch M, Valagussa P, von Minckwitz G, Wickerham DL, Wolmark N, Zhang L
|
|
4.
|
Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. MedStar authors:
- Sugarbaker, Paul H
- Yan, Tristan D
Year: 2012
Citation: - Journal of Clinical Oncology. 30(20):2449-56, 2012 Jul 10.
Institution:
- MedStar Washington Hospital Center
- Washington Cancer Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Research Support, Non-U.S. Gov't
All authors: - Baratti D, Barrios P, Ceelen WP, Chua TC, de Hingh IH, Deraco M, Elias D, Gilly FN, Glehen O, Gomez Portilla A, Gonzalez-Moreno S, Levine EA, Liauw W, Moran BJ, Morris DL, Pelz JO, Piso P, Sardi A, Sugarbaker PH, Van Der Speeten K, Yan TD
|
|
5.
|
Avastin withdrawal symptoms. MedStar authors:
- Lynce, Filipa
- Swain, Sandra M
Citation: - Expert Opinion on Pharmacotherapy. 13(3):293-8, 2012 Feb.
Institution: - Washington Cancer Institute
Medline publication type:
- Editorial
- Research Support, Non-U.S. Gov't
|
|
6.
|
Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. MedStar authors:
Year: 2013
Citation: - Annals of Oncology. 24(10):2630-5, 2013 Oct.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Clark E, Cortes J, Im SA, Im YH, Knott A, Pivot X, Ross G, Swain SM
|
|
7.
|
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. MedStar authors:
Year: 2017
Citation: - Annals of Oncology. 28(5):1050-1056, 2017 May 01
Institution: - MedStar Washington Hospital Center
Medline publication type:
All authors: - Barr PM, Brander DM, Cheson BD, Claxton DF, Cruz AL, Daniel C, Fanning M, Foon K, Gashonia L, Goy A, Henick Bachow S, Hill BT, Howlett C, Isaac K, Kennard KH, Kiselev P, Lamanna N, Lenhart J, Mato AR, Nabhan C, Pu JJ, Schuster SJ, Skarbnik AP, Svoboda J, Timlin C, Ujjani CS, Winter AM, Yacur M, Zent CS
|
|
8.
|
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. MedStar authors:
Year: 2013
Citation: - Lancet Oncology. 14(6):461-71, 2013 May.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Benyunes MC, Campone M, Ciruelos E, Clark E, Cortes J, Ferrero JM, Kim SB, Knott A, Ro J, Ross G, Schneeweiss A, Semiglazov V, Swain SM
|
|
9.
|
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). MedStar authors:
Year: 2017
Citation: - Journal of Clinical Oncology. 35(23):2647-2655, 2017 Aug 10.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Comparative Study
- Journal Article
- Randomized Controlled Trial
All authors: - Asmar L, Blum JL, Brufsky AM, Colangelo LH, Dang CT, Fehrenbacher L, Flynn PJ, Geyer CE Jr, Gomez HL, Hopkins JO, Jacobs SA, Jeong JH, Jones SE, Lyss AP, Mamounas EP, O'Shaughnessy JA, Paul D, Robert NJ, Swain SM, Vukelja SJ, Wolmark N, Yothers G
|
|
10.
|
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. MedStar authors:
Year: 2022
Citation: - Journal of Clinical Oncology. 40(5):438-448, 2022 02 10.
Department: - Associate Dean for Research Development
Medline publication type:
All authors: - Barrios C, Bonnefoi H, Boulet T, De Laurentiis M, Ellis PA, Fehrenbacher L, Gianni L, Gralow J, Harbeck N, Huang CS, Im SA, Im YH, Ito Y, Krop IE, Liu H, Macharia H, Nowecki Z, Shah J, Song C, Swain SM, Toi M, Trask P, Winer EP
|